Cargando…

Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study

PURPOSE: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients in the Omicron era remains unknown. The aim of the study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kneidinger, Nikolaus, Hecker, Matthias, Bessa, Vasiliki, Hettich, Ina, Wald, Alexandra, Wege, Sabine, Nolde, Anna-Barbara, Oldigs, Maike, Syunyaeva, Zulfiya, Wilkens, Heinrike, Gottlieb, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461411/ https://www.ncbi.nlm.nih.gov/pubmed/36083405 http://dx.doi.org/10.1007/s15010-022-01914-8

Ejemplares similares

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021)

The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022)

Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
por: Grüne, Barbara, et al.
Publicado: (2022)

Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
por: Chun, June Young, et al.
Publicado: (2022)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
por: Andrews, Nick, et al.
Publicado: (2022)

Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
por: Carrazco-Montalvo, Andrés, et al.
Publicado: (2022)

A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
por: Manjunath, R, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
por: Chavda, Vivek P, et al.
Publicado: (2022)

The updated strategy to overcome new challenge: Omicron variant (B.1.1.529) pandemic
por: Ri, HyokJu, et al.
Publicado: (2022)

Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients
por: Spensley, Katrina J., et al.
Publicado: (2022)

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2021)

SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!
por: Rahmani, Shayan, et al.
Publicado: (2022)

A study on the effect of natural products against the transmission of B.1.1.529 Omicron
por: Alkafaas, Samar Sami, et al.
Publicado: (2023)

Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater
por: Ahmed, Warish, et al.
Publicado: (2022)

First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador
por: Carrazco-Montalvo, A., et al.
Publicado: (2022)

Clinical Characteristics of Omicron (B.1.1.529) Variant in Children: A Multicenter Study in Spain
por: Molina Gutiérrez, Miguel Ángel, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat assessment and plan of action
por: Choudhary, Om Prakash, et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection
por: Elkoshi, Zeev
Publicado: (2022)

SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
por: Reynolds, Catherine J., et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
por: Mohseni Afshar, Zeinab, et al.
Publicado: (2023)

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)
por: Lu, Yuying, et al.
Publicado: (2023)

SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
por: Ciurkiewicz, M., et al.
Publicado: (2023)

Detection of SARS-CoV-2 Omicron variant (B.1.1.529) infection of white-tailed deer
por: Vandegrift, Kurt J., et al.
Publicado: (2022)

Genome Sequences of 25 SARS-CoV-2 Sublineage B.1.1.529 Omicron Strains in Bangladesh
por: Bin Manjur, Omar Hamza, et al.
Publicado: (2022)

The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance
por: Ren, Shi-Yan, et al.
Publicado: (2022)

The Omicron (B.1.1.529) SARS-CoV-2 variant of concern also affects companion animals
por: Sánchez-Morales, Lidia, et al.
Publicado: (2022)

Knowledge, perception, and fear among the global population towards newly evoked variant Omicron (B.1.1.529)
por: Qureshi, Ali, et al.
Publicado: (2022)

Fractional order mathematical model for B.1.1.529 SARS-Cov-2 Omicron variant with quarantine and vaccination
por: Dickson, S., et al.
Publicado: (2023)

Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases
por: Benny, Libin, et al.
Publicado: (2023)

Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals
por: Leiner, Johannes, et al.
Publicado: (2022)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy
por: Micheli, Valeria, et al.
Publicado: (2022)

Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions
por: Islam, Fahadul, et al.
Publicado: (2022)

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
por: Touret, Franck, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
por: Sheward, Daniel J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_clnee0hm5gbe8c1k6nmikfqlad